3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Anal Cancer Metastatic
1
Interventions
pembrolizumab
3
fludarabine
3
Cyclophosphamide
3
Ipilimumab
2
smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
1
sargramostim
1
reolysin
1
poly ICLC
1
peginterferon alfa-2a
1
osimertinib
1
gusacitinib
1
fludarabine phosphate
1
eprenetapopt
1
epacadostat
1
dabrafenib
1
cobimetinib
1
cemiplimab
1
Vorinostat
1
Temozolomide
1
Radiotherapy
1
Radiation
1
Poly I-C
1
Nivolumab
1
Monatide (IMS 3015)
1
Methods
1
MAPRE1 protein, human
1
Interleukin-2
1
Interleukin-15
1
Interleukin-12
1
IT-101
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Skin Neoplasms
×
reolysin
×
Clear all
NCT03282188
2018-05-04
REO13 Melanoma With of Without GM-CSF
University of Leeds
Phase 1/2
Withdrawn